Revolution Medicines Inc. (RVMD)
High Risk, High Reward: Inside The Revolution Medicines Bull Case
Revolution Medicines is evolving from a clinical-stage biotech to a near-term commercial oncology player, anchored by its RAS(ON) inhibitor platform. RVMD's robust $3.9 billion cash position and additional committed capital support aggressive pipeline expansion and commercial launch readiness, reducing near-term dilution risk. Daraxonrasib's potential FDA approval and commercial launch in pancreatic cancer could fundamentally transform RVMD's financial profile and validate its broader RAS-targeted strategy.
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook again as investors weigh higher spending and pipeline progress.
Revolution Medicines Q2 Earnings Call Highlights
Revolution Medicines NASDAQ: RVMD said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it advances daraxonrasib and other RAS-targeted therapies across pancreatic and lung cancer.
Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript
Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill
The European Medicines Agency said on Tuesday it has begun a rolling review of Revolution Medicines' experimental treatment for patients with metastatic pancreatic cancer.
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.
Revolution Medicines: Strong Data, Big Market (Rating Upgrade)
Revolution Medicines is upgraded to buy as Daraxonrasib delivers practice-changing Phase 3 data in pancreatic ductal adenocarcinoma (PDAC). RVMD's $4B pro forma liquidity supports over two years of aggressive clinical expansion, with cash burn focused on value-driving trials and regulatory submissions. Daraxonrasib's Phase 3 results show a 60% reduction in risk of death and doubled median overall survival in metastatic PDAC, supporting a multi-billion-dollar opportunity.
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from Revolution Medicines while they await what they hope will be a speedy FDA approval.
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.
